Compass Launches Center Of Excellence
Compass Pathways (NASDAQ:CMPS) officially launched the Centre of Excellence, in collaboration with The Sheppard Pratt Institute for Advanced Diagnostics and Therapeutics in Baltimore, Maryland.
This “clinic model” will study and build the best therapy models for psychedelics treatment and work as a site for clinical trials as well as a laboratory for innovation. It will also explore research around COMP360, Compass’ psilocybin drug candidate.
Scott Aaronson MD, Director of Clinical Research at Sheppard Pratt, will lead the center.
“Sheppard Pratt has a long history of excellence in clinical service delivery and commitment to its community of patients,” Compass Pathways CEO George Goldsmith said. “Our Centers of Excellence, beginning with this centre led by the distinguished team at Sheppard Pratt, will help to accelerate our combined work so that we can bring evidence-based innovation, on a large scale, to the people who need
Matt Stang, Founder of DELIC commented, Seeing the traffic increase month over month in combination with the launch of the stores on Reality Sandwich and The Delic is an exciting moment for us at DELIC. This is an important milestone for the company as it shows how we at DELIC are executing on our monetization strategy. The growth of the site also indicates the interest in the sector growing, which will allow us to deliver further value to our shareholders.
Since DELIC s acquisition of Reality Sandwich in 2019, the site had a record traffic month in the month of November 2020. Reality Sandwich has increased monthly average pageviews from 25,000 in 2019 to 220,000 monthly views (2.6 million annualized). The company views this recent data as a key indicator of growing interest in not only our brand, but in the psychedelic sector as a whole.